FDA approves Gilead'''s next-generation HIV PrEP pill, Descovy

Gilead now controls the U.S. HIV pre-exposure prophylaxis market with two separate drugs: Truvada and Descovy, a smaller and safer pill.

Gilead Sciences, the drug giant behind the blockbuster HIV prevention pill Truvada, won FDA approval on Thursday to market Descovy a medication already used by those who have HIV as its next-generation prevention drug.

The final approval follows an August vote in favor of Descovy as a pre-exposure prophylaxis medication, or PrEP, by an FDA advisory panel.
There are some different ways to look at this discovery but it seems to promote indiscriminate, unprotected gay sex, which doesn't seem like a good thing. And these drugs are $$$ expensive.